Wrap Text
Response to possible offer
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
(‘Mediclinic’, the ‘Company’, or the ‘Group’)
FOR IMMEDIATE RELEASE
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO
WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.4 OF THE CITY CODE ON TAKEOVERS AND MERGERS (THE
"CODE") AND DOES NOT CONSTITUTE AN ANNOUNCEMENT OF A FIRM INTENTION TO MAKE AN OFFER UNDER
RULE 2.7 OF THE CODE. THERE CAN BE NO CERTAINTY THAT ANY OFFER WILL BE MADE.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION.
9 June 2022
RESPONSE TO POSSIBLE OFFER
The Board of Mediclinic International plc (“Mediclinic” or the “Company”) notes the announcement made by the consortium
comprising Remgro Limited (“Remgro”) and MSC Mediterranean Shipping Company SA, acting through its wholly-owned
subsidiary, SAS Shipping Agencies Services Sàrl, (together the “Consortium”).
The Board of Mediclinic confirms that, on 26 May 2022, it received an unsolicited and conditional proposal from the Consortium,
concerning a possible cash offer to acquire the entire issued and to be issued ordinary share capital of Mediclinic not already
owned by Remgro at 460 pence per share plus the Mediclinic proposed final dividend for the financial year ended 31 March
2022 of 3 pence per share (the “Proposal”).
The Board of Mediclinic (excluding the Remgro representative) considered the Proposal, together with its advisers, and
concluded that it significantly undervalued Mediclinic and its future prospects. Accordingly, on 31 May 2022, the Board of
Mediclinic (excluding the Remgro representative) unanimously rejected the Proposal.
There can be no certainty that any offer will be made for the Company.
Shareholders are urged to take no action in relation to the possible offer at this time.
This announcement has been made without the consent of the Consortium.
Any offer for Mediclinic is governed by the City Code on Takeovers and Mergers. Under Rule 2.6(a) of the Code, the Consortium
must by not later than 5.00 p.m. on 7 July 2022 either announce a firm intention to make an offer for Mediclinic in accordance
with Rule 2.7 of the Code or announce that it does not intend to make an offer, in which case the announcement will be treated
as a statement to which Rule 2.8 of the Code applies. This deadline will only be extended with the consent of the Panel in
accordance with Rule 2.6(c) of the Code.
The person responsible for arranging for the release of this announcement on behalf of Mediclinic is Jurgens Myburgh, CFO.
ENQUIRIES
Mediclinic International plc +44 (0)20 3786 8181
James Arnold
Head of Investor Relations
ir@mediclinic.com
Morgan Stanley (Financial Adviser to Mediclinic) +44 (0)20 7425 8000
Matthew Jarman
Tom Perry
Anthony Zammit
Obaid Mufti
FTI Consulting (Media enquiries)
Ben Atwell/Ciara Martin – UK +44 (0)20 3727 1000
Sherryn Schooling – South Africa +27 (0)21 487 9000
Mediclinic International plc
Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: https://www.mediclinic.com/
Corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Ltd)
NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd
Disclosure requirements of the Code
Under Rule 8.3(a) of the Code, any person who is interested in 1% or more of any class of relevant securities of an offeree
company or of any securities exchange offeror (being any offeror other than an offeror in respect of which it has been
announced that its offer is, or is likely to be, solely in cash) must make an Opening Position Disclosure following the
commencement of the offer period and, if later, following the announcement in which any securities exchange offeror is first
identified. An Opening Position Disclosure must contain details of the person’s interests and short positions in, and rights to
subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s). An Opening
Position Disclosure by a person to whom Rule 8.3(a) applies must be made by no later than 3.30 pm (London time) on the 10 th
business day following the commencement of the offer period and, if appropriate, by no later than 3.30 pm (London time) on
the 10th business day following the announcement in which any securities exchange offeror is first identified. Relevant persons
who deal in the relevant securities of the offeree company or of a securities exchange offeror prior to the deadline for making
an Opening Position Disclosure must instead make a Dealing Disclosure.
Under Rule 8.3(b) of the Code, any person who is, or becomes, interested in 1% or more of any class of relevant securities of
the offeree company or of any securities exchange offeror must make a Dealing Disclosure if the person deals in any relevant
securities of the offeree company or of any securities exchange offeror. A Dealing Disclosure must contain details of the
dealing concerned and of the person’s interests and short positions in, and rights to subscribe for, any relevant securities of
each of (i) the offeree company and (ii) any securities exchange offeror, save to the extent that these details have previously
been disclosed under Rule 8. A Dealing Disclosure by a person to whom Rule 8.3(b) applies must be made by no later than
3.30 pm (London time) on the business day following the date of the relevant dealing.
If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or
control an interest in relevant securities of an offeree company or a securities exchange offeror, they will be deemed to be a
single person for the purpose of Rule 8.3.
Opening Position Disclosures must also be made by the offeree company and by any offeror and Dealing Disclosures must
also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1,
8.2 and 8.4).
Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing
Disclosures must be made can be found in the Disclosure Table on the Takeover Panel’s website at
www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the offer period
commenced and when any offeror was first identified.
You should contact the Takeover Panel’s Market Surveillance Unit on +44 (0) 20 7638 0129 if you are in any doubt as to
whether you are required to make an Opening Position Disclosure or a Dealing Disclosure.
Financial adviser
Morgan Stanley & Co. International plc (“Morgan Stanley”) which is authorised by the Prudential Regulation Authority and
regulated by the Financial Conduct Authority and the Prudential Regulation Authority in the UK is acting as sole financial
adviser exclusively for Mediclinic and no one else in connection with the matters set out in this announcement. In connection
with such matters, Morgan Stanley, its affiliates and their respective directors, officers, employees and agents will not regard
any other person as their client, nor will they be responsible to any other person for providing the protections afforded to their
clients or for providing advice in connection with the contents of this announcement or any other matter referred to herein.
Website
In accordance with Rule 26.1 of the Code, a copy of this announcement will be available (subject to certain restrictions relating
to persons resident in restricted jurisdictions) on Mediclinic’s website at https://investor.mediclinic.com/ by no later than 12
noon (London time) on the business day following the date of this announcement. The content of this website is not
incorporated into, and does not form part of, this announcement.
Rule 2.9
In accordance with Rule 2.9 of the Code, as at the date of this announcement, Mediclinic’s issued share capital comprises
737,243,810 ordinary shares of GBP0.10 each held outside treasury (ISIN: GB00B8H8Z88).
Mediclinic has a primary listing on the Main Market of the LSE, with secondary listings on the JSE in South Africa and the NSX
in Namibia.
LEI: 2138002S5BSBIZTD5I60
Date: 09-06-2022 09:17:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
Sharenet Sites 
